Health Economics›Gastrointestinal stromal tumor›Adjuvant therapy

Adjuvant therapy

Gastrointestinal stromal tumor · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Imatinib monotherapy Variant #16	—	R 2 801	28d	—	—	2	R 5 603 PFS proxy	2
Placebo Partial	—	—	—	~0.9 mo	~7.6 mo	—	—	4

2 of 2 regimens shown